William Blair Issues Negative Estimate for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities researchers at William Blair reduced their Q2 2025 earnings estimates for shares of Elanco Animal Health in a research report issued on Wednesday, May 7th. William Blair analyst B. Vazquez now forecasts that the company will post earnings of $0.19 per share for the quarter, down from their previous estimate of $0.22. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health's Q2 2026 earnings at $0.26 EPS.

Several other research analysts also recently commented on ELAN. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Finally, Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $15.00.

Elanco Animal Health Stock Performance

ELAN traded up $0.86 during trading on Friday, hitting $12.82. The stock had a trading volume of 7,583,788 shares, compared to its average volume of 4,997,314. The firm has a market cap of $6.36 billion, a PE ratio of 32.04, a P/E/G ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a 50 day simple moving average of $9.93 and a 200-day simple moving average of $11.42.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.34 EPS. Elanco Animal Health's quarterly revenue was down 1.0% compared to the same quarter last year.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB acquired a new position in Elanco Animal Health in the third quarter valued at about $35,000. Franklin Resources Inc. boosted its position in Elanco Animal Health by 14.0% in the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after buying an additional 45,795 shares in the last quarter. Everence Capital Management Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at about $209,000. Harbor Capital Advisors Inc. boosted its position in Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after buying an additional 209,734 shares in the last quarter. Finally, 180 Wealth Advisors LLC boosted its position in Elanco Animal Health by 10.4% in the fourth quarter. 180 Wealth Advisors LLC now owns 26,732 shares of the company's stock valued at $324,000 after buying an additional 2,525 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. The trade was a 9.86% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.89% of the stock is currently owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.